These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 30327656)
1. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. van Willigen WW; Bloemendal M; Gerritsen WR; Schreibelt G; de Vries IJM; Bol KF Front Immunol; 2018; 9():2265. PubMed ID: 30327656 [TBL] [Abstract][Full Text] [Related]
2. Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect. Nava S; Lisini D; Frigerio S; Bersano A Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830221 [TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Boudewijns S; Bloemendal M; Gerritsen WR; de Vries IJ; Schreibelt G Hum Vaccin Immunother; 2016 Oct; 12(10):2523-2528. PubMed ID: 27322496 [TBL] [Abstract][Full Text] [Related]
4. In vivo cancer vaccination: Which dendritic cells to target and how? Chiang CL; Kandalaft LE Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423 [TBL] [Abstract][Full Text] [Related]
5. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238 [TBL] [Abstract][Full Text] [Related]
6. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Versteven M; Van den Bergh JMJ; Marcq E; Smits ELJ; Van Tendeloo VFI; Hobo W; Lion E Front Immunol; 2018; 9():394. PubMed ID: 29599770 [TBL] [Abstract][Full Text] [Related]
7. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743 [TBL] [Abstract][Full Text] [Related]
8. A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. Vo MC; Ahn SY; Chu TH; Uthaman S; Pillarisetti S; Uong TNT; Lakshmi TJ; Kim M; Song GY; Jung SH; Yang DH; Ahn JS; Kim HJ; Park IK; Lee JJ Cell Mol Immunol; 2021 Jun; 18(6):1599-1601. PubMed ID: 33782574 [No Abstract] [Full Text] [Related]
9. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Obeid J; Hu Y; Slingluff CL Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060 [TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Overwijk WW Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603 [TBL] [Abstract][Full Text] [Related]
11. Clinical application of dendritic cells in cancer vaccination therapy. Svane IM; Soot ML; Buus S; Johnsen HE APMIS; 2003; 111(7-8):818-34. PubMed ID: 12974783 [TBL] [Abstract][Full Text] [Related]
12. A review of dendritic cell therapy for cancer: progress and challenges. Mantia-Smaldone GM; Chu CS BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406 [TBL] [Abstract][Full Text] [Related]
13. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Galati D; Zanotta S Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963 [TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination as a treatment modality for melanoma. Eubel J; Enk AH Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246 [TBL] [Abstract][Full Text] [Related]
16. Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses. Ogasawara M; Miyashita M; Ota S Ther Apher Dial; 2018 Jun; 22(3):266-277. PubMed ID: 29851270 [TBL] [Abstract][Full Text] [Related]
17. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-based cancer vaccination: quo vadis? Dauer M; Schnurr M; Eigler A Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953 [TBL] [Abstract][Full Text] [Related]